Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3277511A (NTHi Mcat vaccine) 3-dose schedule in healthy smokers
NCT03443427Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of GSK3277511A in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects Reported With Each Solicited Local Adverse Event (AE) (Any and Grade 3) Within Each Vaccination Schedule, Number of Subjects Reported With Each Solicited General Adverse Event (AE) (Any and Grade 3) Within Each Vaccination Schedule and 3 more. Started Mar 2018; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03443427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443427.